Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
March 6, 2010 by biotechconnection.com · Leave a Comment
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.
Read more on PR Newswire via Yahoo! Finance